Month: September 2022

AN INTERESTING VIEW OF THE INEVITABILITY OF PERSONALIZED MEDICINE, and how it may already be shaping medicine. While the author states that our ability to interpret the kinds of data coming from whole genome screening in increasing rapidly, this is not supported by general experience. At the present time, the tools are advancing faster than our development of thorough, expert interpretations of what the data mean at a medical level. http://social.eyeforpharma.com/column/personalized-medicine-new-technologies-improve-personalization-and-precision View in LinkedIn

THE LEAN STARTUP METHOD is about adopting an experimental method in the search for customer access. This makes perfect sense for some companies but not for technology companies who are years away from a product and are unlikely ever to meet the customer. Specialty Pharma companies have years of formulation, preclinical testing, and eventually clinical trials to get a licensable product. Overall, the steps are pretty clear, although the outcomes are not. In these cases, a well-articulated plan of the steps and costs are valuable (flexible) roadmaps, and product forecasts will always be wrong. http://lnkd.in/EQumPg View in LinkedIn

INDIA IS FIGURING OUT ITS IP POLICY as this thoughtful commentary outlines. It has been clear to me for some years that Indian pharmaceutical patents are very shrewd, and also that the IP industry including patent challenges are sophisticated. The key is to not cave to Activist views and keep the middle ground where patented innovator drugs from abroad are respected under patent treaties, and also to develop a sensible way to get approved Western drugs through Indian trials while not becoming a case for The Constant Gardener. P http://lnkd.in/pqYStD View in LinkedIn

STEPHEN HAWKIN IS A SYMBOL OF THE POSSIBLE. ALS has ravaged his body, but this brilliant person lives an active cerebral life by communicating by a computer through eye movements only. We all know who he is. He has quietly entered every household. But the remarkable brain-computer interface that makes all this possible is something we have appeared uncurious about. This is more than a prototype. But what is that like subjectively? What is it like to have an athlete's brain and no body? What are the possibilities of hooking up a brain to a machine? View in LinkedIn

ALLIANCES AND MERGERS BETWEEN SMEs TODAY MAKES SENSE, especially in the Biopharma sector. VCs have withdrawn, and Big Pharma is bearing the weight of solicitations, but is overwhelmed and the response times have become ridiculous. Most companies looking for collaborations and capital have failed to explore the layers of smaller companies below the giants. Many have capital, many are active in BD, and are interested in product licenses and filling their pipelines. In this economic climate, it is inevitable that market efficiencies will lead to combined similar programs. View in LinkedIn

INDIA PIONEERED THE 2,000 USD CAR, AND NOW THE 800 USD HEART SURGERY. A famous heart surgeon who founded a chain of low-cost clinics, believes that only 10% of those needing heart surgery can afford it, and that the current Western healthcare business model is simply wrong. This innovative surgeon is remaking the healthcare model in India, giving inexpensive access to the poor. He plans to expand into Africa. Currently, the new heart clinic performs the most heart surgeries per day worldwide, and the key to success will be a comparable success rate to the West. This is a bold experiment. http://lnkd.in/PNbghT View in LinkedIn

CHINA HAS BECOME THE GO-TO PLACE FOR INDIAN ENTREPRENEURS, with its high-octane economic growth, investment in infrastructure, and welcoming attitude. This vibrant and hard-working (and complicated) country is quietly turning the economic power axis of the world, with India in the wings. Giant populations, an emerging middle-class, creating "medical cities", securing worldwide mineral rights, and creating the New Harvards of The East, China is undeniably on a world leadership course. If it cleaned up its patent protection climate and certain business practices, it will be unstoppable. http://lnkd.in/4533r8 View in LinkedIn

MOEBIO AND D-HEALTH BARCELONA are modeled on the prestigious Stanford University Biodesign Fellowship and opens Sept 2013. Since 2001, the Stanford program created 26 companies, raised 200 M USD, created 500 jobs and treated 150,000 patients with technology developed in-house. D-HEALTH BARCELONA is a new talent incubator, to train health innovators, tackle real medical issues and create new companies. It will be disruptive, entrepreneurial, and link health innovators and investors, to build new businesses. It was created by BioCat, the Catalan biotech organization charged with innovation. View in LinkedIn

D-HEALTH BARCELONA;" "" "Twitter@moebiobarcelona. View in LinkedIn

PHARMA AND VENTURE CAPITAL ALLIANCES ARE ON THE INCREASE. GSK has partnered with Avalon Ventures in a 495 M USD deal, in a trend that J&J and Sanofi are also creating. The GSK deal is on top of having their own SR ONE VC fund who is collaborating with Sanderling Ventures (who partner also with J&J and Index Ventures). Sanofi has a collaboration with Third Rock Ventures. This is a welcome trend and shows that Big Pharma is reinventing its R&D model to be less NIH. http://lnkd.in/JR69EC View in LinkedIn